Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:MYOV Myovant Sciences (MYOV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Myovant Sciences Stock (NYSE:MYOV) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Myovant Sciences alerts:Sign Up Key Stats Today's Range$26.98▼$27.0050-Day Range$26.88▼$26.9952-Week Range$7.67▼$27.06Volume2.26 million shsAverage Volume1.17 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Read More… [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Receive MYOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MYOV Stock News HeadlinesVivek Ramaswamy's Net Worth: How Donald Trump's Key Aide Made His BillionsNovember 13, 2024 | msn.comBorn To Indian Immigrants, Now Part Of Trump's 'DOGE' Plan – How Vivek Ramaswamy Became A Billionaire By Shedding Unprofitable Pharma AssetsNovember 13, 2024 | msn.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 27, 2024 | Crypto Swap Profits (Ad)Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsightSeptember 25, 2024 | finance.yahoo.comThe Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | OpinionSeptember 12, 2024 | newsweek.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comGynecology Collaboration, R&D, and Licensing Deals Trends Report 2024May 7, 2024 | finance.yahoo.comWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline DrugsApril 18, 2024 | uk.finance.yahoo.comSee More Headlines MYOV Stock Analysis - Frequently Asked Questions How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd. (NYSE:MYOV) posted its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.11. The business had revenue of $77.90 million for the quarter, compared to analysts' expectations of $72.67 million. When did Myovant Sciences IPO? Myovant Sciences (MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings10/26/2021Today11/27/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webwww.myovant.com Phone442074003351FaxN/AEmployees407Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,980,000.00 Net Margins-48.47% Pretax Margin-42.81% Return on EquityN/A Return on Assets-39.36% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.45 Sales & Book Value Annual Sales$230.97 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-5.35Miscellaneous Outstanding Shares97,240,000Free Float95,388,000Market Cap$2.62 billion OptionableNot Optionable Beta2.17 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NYSE:MYOV) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
